FDA Approves Moderna’s New mRNA Flu Vaccine for Adults 50 and Older
The U.S. Food and Drug Administration (FDA) has approved Moderna's new mRNA seasonal flu vaccine, mFLUSIVA, which will be available for individuals aged 50 and older starting with the 2026-2027 respiratory illness season.
Raleigh Durham, NC, August 6, 2026 —
The U.S. Food and Drug Administration (FDA) has granted approval to Moderna for its new messenger RNA (mRNA) based seasonal flu vaccine, named mFLUSIVA.
This newly approved vaccine is designated for use in individuals aged 50 years and older.
Availability of mFLUSIVA is slated to commence with the 2026-2027 respiratory illness season.
The approval marks a significant development in vaccine technology, utilizing mRNA, the same platform employed in some COVID-19 vaccines, to target seasonal influenza strains.
Moderna’s mFLUSIVA aims to provide an alternative option for seasonal flu immunization for the specified age group.
Further details regarding the vaccine’s efficacy and specific formulation for the 2026-2027 season are expected as the availability date approaches.
Story summarized from the original created by web.operations@abc11mail.com(WTVD-TV Raleigh-Durham) on abc11.com, see more information here.
